{"id":5351,"date":"2022-07-28T19:54:20","date_gmt":"2022-07-28T19:54:20","guid":{"rendered":"https:\/\/biotechsa.com\/2\/?p=5351"},"modified":"2026-03-10T13:02:05","modified_gmt":"2026-03-10T19:02:05","slug":"hospital-acquired-drug-resistant-infections-deaths-rose-15-from-2019-20-cdc","status":"publish","type":"post","link":"https:\/\/biotechsa.com\/2\/noticias\/hospital-acquired-drug-resistant-infections-deaths-rose-15-from-2019-20-cdc\/","title":{"rendered":"Hospital acquired drug resistant infections, deaths rose 15% from 2019-20: CDC"},"content":{"rendered":"\n
<\/span><\/div>

Hospital-acquired drug-resistant infections, deaths rose 15% from 2019-20: CDC<\/strong><\/h3>\n

According to Becker\u2019s Hospital Review, findings from the CDC\u2019s \u201cCOVID-19: US Impact on Antimicrobial Resistance, Special Report 2022\u201d show that the pandemic caused a 15% increase in antimicrobial-resistant infections and deaths from 2019 to 2020.<\/p>\n

Contributing factors to the CDC\u2019s findings include the lack of infection prevention and control guidance in hospitals during the pandemic, which are necessary in preventing antimicrobial-resistant infections, and the excessive use of antibiotics. Challenges associated with limited access to personal protective equipment, staffing shortages and longer patient stays during the pandemic may have also added to the rise in antimicrobial-resistant infections.<\/p>\n

Over 29,400 people died from antimicrobial-resistant infections during the first year of the pandemic, with 40% of those patients becoming infected during their hospital stay. According to this report, the CDC estimates that 2.8 million antimicrobial-resistant infections occurred in the U.S. each year, resulting in more than 35,000 deaths.<\/p>\n

Michael Craig, director of the CDC\u2019s Antibiotic Resistance Coordination and Strategy Unit states that \u201cthe setback can and must be temporary. The COVID-19 pandemic has unmistakably shown us that antimicrobial resistance will not stop if we let down our guard; there is no time to waste.\u201d Denise Cardo, MD, director of CDC’s Division of Healthcare Quality Promotion, adds \u201cwe need to emphasize and expand the implementation of the effective prevention strategies that are already in CDC’s toolbox to all healthcare facilities.\u201d<\/p>\n

Click here to view this article.<\/a><\/p>\n

July 2022<\/p>\n<\/div><\/div>

TRADUCCI\u00d3N DE GOOGLE:<\/span><\/strong><\/p>\n

\n<\/div><\/div><\/div><\/div>

Infecciones farmacorresistentes adquiridas en hospitales, las muertes aumentaron un 15 % entre 2019 y 2020: CDC<\/strong><\/h3>\n

Seg\u00fan Becker’s Hospital Review, los hallazgos del “COVID-19: Impacto de EE. UU. en la resistencia a los antimicrobianos, Informe especial 2022” de los CDC muestran que la pandemia provoc\u00f3 un aumento del 15 % en las infecciones y muertes resistentes a los antimicrobianos entre 2019 y 2020.<\/p>\n

Los factores que contribuyeron a los hallazgos de los CDC incluyen la falta de orientaci\u00f3n para la prevenci\u00f3n y el control de infecciones en los hospitales durante la pandemia, que son necesarios para prevenir infecciones resistentes a los antimicrobianos, y el uso excesivo de antibi\u00f3ticos. Los desaf\u00edos asociados con el acceso limitado a equipos de protecci\u00f3n personal, la escasez de personal y las estad\u00edas m\u00e1s prolongadas de los pacientes durante la pandemia tambi\u00e9n pueden haber contribuido al aumento de las infecciones resistentes a los antimicrobianos.<\/p>\n

M\u00e1s de 29 400 personas murieron a causa de infecciones resistentes a los antimicrobianos durante el primer a\u00f1o de la pandemia, y el 40 % de esos pacientes se infectaron durante su estad\u00eda en el hospital. Seg\u00fan este informe, los CDC estiman que cada a\u00f1o ocurrieron 2,8 millones de infecciones resistentes a los antimicrobianos en los EE. UU., lo que result\u00f3 en m\u00e1s de 35 000 muertes.<\/p>\n

Michael Craig, director de la Unidad de Estrategia y Coordinaci\u00f3n de Resistencia a los Antibi\u00f3ticos de los CDC, afirma que \u201cel contratiempo puede y debe ser temporal. La pandemia de COVID-19 nos ha demostrado inequ\u00edvocamente que la resistencia a los antimicrobianos no se detendr\u00e1 si bajamos la guardia; No hay tiempo que perder.” Denise Cardo, MD, directora de la Divisi\u00f3n de Promoci\u00f3n de la Calidad de la Atenci\u00f3n M\u00e9dica de los CDC, agrega que \u201cnecesitamos enfatizar y ampliar la implementaci\u00f3n de las estrategias de prevenci\u00f3n efectivas que ya est\u00e1n en la caja de herramientas de los CDC en todos los centros de atenci\u00f3n m\u00e9dica\u201d.<\/p>\n

Haga clic aqu\u00ed para ver este art\u00edculo.<\/a><\/p>\n

julio 2022<\/p>\n<\/div><\/div><\/div><\/div><\/div>

\n\n